Given relatively modest remission rates for antidepressant treatments available, there is a need for approaches that help tailor existing treatments to the individual in order to improve remission rates. In addition, such techniques should be clinically actionable and well validated in blinded out-of-sample validations. Here we introduce the concept of Stratified Psychiatry, that is better suited for implementation in clinical practice, and demonstrate that Brainmarker-I, an EEG biomarker, can successfully help stratify patients between 1-Hz right and 10-Hz left rTMS, as well as for ECT and various other antidepressant treatments, as a clinically actionable stratification marker, with an effective gain of 24% more remission on the group level. Transdiagnostic application off Brainmarker-I in ADHD yielded +29-36 higher remission rates in blinded out-of-sample validations.

The presenter is Dr. Martijn Arns who is the research director at the Brainclinics Foundation and associate professor at Maastricht University, Faculty of Psychology & Neuroscience. His main interest is Stratified Psychiatry and Precision Psychiatry for Depression and ADHD, and brain stimulation techniques such as rTMS.

Register here free of charge. We look forward to welcoming you to this webinar!